Leaders in Pharmaceutical Business Intelligence (LPBI) Group

• Bio Instrumentation in Experimental Life Sciences Research
• Drug Delivery Platform Technology
• Cardiac & Vascular Repair Tools Subsegment
• Frontiers in Cardiology
• Medical Devices
• Stents & Tools
• Pharmacotherapy of Cardiovascular Disease
• Medical Devices R&D Investment
• Origins of Cardiovascular Disease
• Technology Transfer: Biotech and Pharmaceutical
• Nanotechnology for Drug Delivery

Tim Wu, MD, Msc, PhD(c)

Personal Biography

Dr. Wu, is the Scientific Founder and Chairman of the Board of MMG, adjunct professor of Biomedical Engineering at University of Massachusetts, and the inventor of the proposed technologies. As a medical doctor with intensive professional training and clinical experience in interventional cardiology, Dr. Wu is also well educated in the area of mechanical design, biomaterial engineering, business management and medical device regulatory affairs.  He has over 20 years of research experience in coronary artery disease including the development of angioplasty balloon catheter, guide wires, coronary arterial stent, biotissue materials, cardiovascular gene therapies and anti-restenosis agent testing applied in a variety of animal vascular models including the pig coronary artery, the carotid and iliac arteries and the rat carotid common artery.  Dr. Wu was involved in the development of the 1^st generation DES when he worked as a Research Scientist at NitroMed, Inc. where he directed the development and pre-clinical evaluation of DES sponsored by J&J.  Previously, Dr. Wu designed a miniature stent—-a featured drug delivery platform for drug delivery in a small vessel under the NIH SBIR program.

Most recently, he developed a potent anti-restenosis formulation, Combo® drug, and a highly biocompatible and biodegradable polymer (BioDe®) at VasoTech (MMG) and directed a series of in-vitro and in-vivo testing.   Prior to starting MicroMedical Group, Inc, Dr. Wu was a Research Director at BRM Company (Worcester, MA), responsible for all research projects and contract service related to cardiovascular diseases at both GLP and non-GLP levels such as biocompatibility studies, toxicity evaluation, PK studies, efficacy/performance testing in a variety of animal models, etc.  Dr. Wu was the PI or core investigator on several NIH funded projects in the area of cardiovascular diseases over the past several years and has serviced NIH as a grant reviewer of NIH SBIR grant applications for Bioengineering, Surgical Science and Technology (SBTS, cardiovascular Devices), and  Biomaterials, Delivery Systems and Nanotechnology.

PATENTS

1. Tim Wu, et al: Anti-Restenosis Composition and Methods of Use. (11/144.917)
2. Tim Wu, et al: Biodegradable Polymer and Its Methods of Use. (11/843.528)
3. Tim Wu, et al: Anti-Restenosis coating and uses thereof. (12/209.104)
4. Tim Wu, et al: Fully biodegradable drug-eluting stent(61/368833)
5. Tim Wu, et al: biodegradable drug eluting stent and the methods of making the same.( 61/427,141)
6. Tim Wu, et al: Biodegradable stent formed with polymer-bioceramic and methods of making the same (13/014,750).
7. Tim Wu, et al: Fully biodegradable drug eluting stent pattern(61/488748)

EDUCATION

INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Linyi Medical School, P.R.China	MD	1981-1985	Medicine
TongJi Medical University, P.R.China	Fellow(MS)	1985-1988	Cardiology
Harvard Medical School, Boston, MA	Postdoctoral	1995-1998	Cardiology
Wentworth Institute of Technology, Boston, MAOversea Chinese Enterprise Association at MIT, MA Massachusetts Biotechnology Council, Boston, MA Northeastern University, Boston, MA   University of Massachusetts Lowell	Certificate Certificate Certificate Certificate PhD	2001-2003 2000-2001 1998——- 2006–2007 2010–2013	Mechanical EngineeringBusiness Administration. Clinical Research Affairs Medical Device Regulatory Affairs Biomedical Engineer& Biomaterial (Plastic Engineering)

WORK EXPERIENCE

1988—1993,            Clinical Cardiologist, Qingdao University, School of Medicine, Qingdao, China

Interventional Cardiologist.

Laser angioplasty and laser ablation of myocardium for arrhythmias.

1993—1995, Visiting Scholar, Cardiovascular Research, St. Elizabeth Hospital, Tufts University, Boston, MA

Gene Therapies for both myocardial ischemia and arterial stenosis.

Angiogenesis investigation for myocardial ischemia

1995—1998,            Principle Investigator, Cardiovascular Research Center, Beth Israel Hospital, Harvard Medical School, Boston, MA

Angiogenesis and gene therapies for myocardial ischemia and arterial restenosis

In vivo drug (include both angiogenesis and anti-restenosis drugs) efficacy evaluation for pharmaceutical companies.

Performance testing of interventional devices including balloon catheter, stent, drug deliver stent for medical device companies.

1998—2000,            Senior Research Scientist, Cardiovascular Group, NitroMed, Inc. Bedford, MA

Preclinical investigation of NO-Taxel and NO-Sirolimus coated drug eluting stents.

Morphorpathologic analysis of in-stent restenosis.

2000—-2006,Research Director, Biomedical Research Models, Inc., Worcester, MA

In charged of In-stent Restenosis model development in small rodent and larger animals.

Designed  rat carotid artery specific miniature stent for rat carotid artery restenosis model

Developed independently the pathology protocol for studying In-stent Restenosis, including plastic embedding and subsequent computerized morphometric analysis.

In charged of  all preclinical contract testing related to cardiovascular disease, particular in the area of in-stent restenosis and  myocardial ischemia models.

2007-Present,            President and CTO, MicroMedical Group, Inc.(VasoTech) Lowell, MA           

Designed MM®Metal Stent and MM® MiniStent.

Developed a Powerful Anti-Restenosis Formulation—Combo®.

Developing Biocompatible and Biodegradable Material–BioDe® polymer for DES.

Developing  a new generation of Drug-Eluting stent—-PowerStent®

Designed a microcatheter system for small vessel and neurovascular intervention

Initiated the SmartGel® biodegradable drug eluting hydrogel for ischemic tissue repair.

2009-Present,            Adjunct Professor, Biomedical Engineering Program, University of Massachusetts Lowell

SPONSORED RESEARCH BY NIH

1 R44HL091579-01(Tim Wu)                                                06/01/08-06/30/2012

NIH SBIR Fast-Track                                                            Principle Investigator

Novel Biodegradable Polymer and Its Coated Drug Eluting Stent           

The goal of this Fast-Track proposal is to characterize VasoTech’s newly developed biodegradable polymer(BioDe® polymer) and further apply it to develop a new generation of drug-eluting stent—PowerStent® drug eluting system.

1 R43 DK061122-01A2 (Tim Wu)                                    08/012004–07/30/2006

NIH SBIR Phase I                                                              Principal Investigator

In-Stent Stenosis Model in Type 2 Diabetic Rats

The objective of this proposal is to develop an in-stent restenosis models in diabetic rat small carotid arteries. In the project, a rat carotid artery specific miniature stent and a rat carotid arterial stenting model were developed

2 R44 DK53679-01 (Dennis Guberski)                                    01/01/2001-12/31/02/02

NIH SBIR Phase II                                                            Core Investigator

The BBZDR rat, New Model of Obesity and Type 2 Diabetes

The objective of this proposal is to characterize the complications of an experimental model of Type 2 diabetes mellitus.  Diabetic complications to be studied include Neuropathy, Nephropathy, Retinopathy and Cardiovascular disease.

1 R43 HL081038 (Acton Susan and Tim Wu) 05/012005-04-30/2007

SBIR Phase I application                                             Principal Investigator for subcontract

A Novel Mouse Model of Coronary Heart Disease

The overall goal of this program is to fully characterize a new animal model system for human coronary heart disease (CHD). The premiere model is a double knockout mouse that has null mutations in the genes for SR-BI (HDL receptor) and apoE (SR-BI/apoEdKO) and which has most of the pathologies of human CHD.

 

ACADEMIC HONORS

 

2004-2007 Reviewer of NIH SBIR/STTR grant application for study section: Bioengineering, Surgical Science and Technology (Cardiovascular Device)

2009–            Reviewer of NIH SBIR/STTR study section: Small Business: Biomaterials, Delivery Systems, and Nanotechnology (IMST 13)

1989-1993 Reviewer, The Journal of Chinese Laser (For laser Medicine Section)

1994-1994 Excellent Award, Basic and Intermediate Immunohistochemistry Workshop, Signet Inc. MA

 

PUBLICATIONS

BOOKS

• Tiangen Wu (Tim Wu) ,Zaiying Lu et al, The Advances of Nitrate Drug Therapies,   1993, Qingdao University Press, Qingdao, P.R.China.
• Tim Wu and Stephen McCarthy, Coronary Arterial Disease, Chapter 10: Coronary Artery Drug-Eluting Stent: From Structure to Clinical. P: 198-2242011, InTech, Publisher, March, 2012.

PEER REVIEWED ARTICLES 

        

• Xiaodong Ma, Tim Wu, Michael P. Robich, et al. Drug-Eluting Stents. International Journal of Clinical and Experimental Medicine. 2010;3(3):192-201.
• Shizu Oyamada, Xiaodong Ma, Tim Wu, Michael P. Robich, Cesario Bianchi, Frank W. Sellke, Roger J. Laham. In Vivo Biocompatibility Comparison Between Novel Biodegradable Polymer and Existing Non-Biodegradable Polymer Coated Stents. JACC. 2010, 55(10A): A122.E1140.
• Xiaodong Ma, Shizu Oyamada, Tim Wu, et al. In Vitro and In Vivo Degradation of Poly (D, L-Lactide -Co-Glycolide)/Amorphous Calcium Phosphate Copolymer Coated on Metal Stents.  Journal of Biomedical Materials Research: Part A, Volume 96A, Issue 4, pages 632–638, 15 March 2011.
• Xiaodong Ma, Shizu Oyamada, Tim Wu, et al. Biocompatibility Study of Poly (D, L-Lactide -Co-Glycolide)/Amorphous Calcium Phosphate Coated Stents in Normal Rat Aortas. (Submitted to Acta Biomaterilia).
• Xiaodong Ma, Shizu Oyamada, Fan Gao, Tim Wu, et al. Paclitaxel/Sirolimus Combination Coated Drug-eluting Stent: In Vitro and In Vivo Drug Release Studies. J.of Pharmaceutical and Biomedical Analysis, 2011;54(4):807
• Oyamada*, Xiaodong Ma*, Tim Wu, et al. Trans-Iliac Rat Aorta Stenting: A Novel High Throughput Preclinical Stent Model for Restenosis and Thrombosis. J of Surgical Research, 2011 166(1): e91-e95.
• Rebecca S. Tirabassi, Joan F. Flanagan, Tim Wu, Edward H. Kislauskis, and Dennis L.Guberskis. TheBBZDR/Wor rat model for investigation the complication of type 2 diabetes mellitus. Natl Acad of  Sci ILAR Journal, 45(3).
• Kaori Sato, Tiangen Wu, Roger J. Laham, Robert B. Johnson, Pamela Douglas, Jianyi Li, Frank   W. Sellke, Stuart Bunting, Michael Simons, Mark J.Post. Efficacy of Intracoronary or  intravenous VEGF 165 in a pig model of chronic myocardial ischemia. JACC 37:2:616-623.
• Brodgi E., Wu T., Namiki A., Isner J. M. Indirect angiogenetic cytokines upregulate VEGF and bFGF expression in vascular smooth muscle cells, where hypoxia upregulate VEGF expression  only. Circulation  90: 649-652, 1994.
• Edi Brodgi, Tiangen Wu, Gina Schatteman, Elizabeth A. Kim, LybaVarticovski Jeffrey M. Isner.  Hypoxia-induced paracrine regulation of VEGF receptor expression. J. Clin. Invest., 97(2):469-476,  1996.
• Atsushi Namiki, Edi Brodgi, Tiangen Wu, Marianne Kearney, Jeffrey M. Isner at al.  Hypoxia induced vascular endothelia growth factor mRNA expression and protein production in human  endothelial cells in vitro. J. Biol. Chem., 270(52): 31189-31195, 1995.
• Tiangen Wu, Zaiying Lu. Comparison between laser and electrical ablation of ventricle in dogs:  Hemodynamic, pathological and electrophysiological observation. J of Tongji Medical University. 12(4): 237-42, 1992.
• Tiangen Wu, Zaiying Lu. A comparative stud of the effects between ND-YAG laser photoablation  and electrical shock ablation in myocardium in dogs. Pace and Heart 4(3): 143-6,1992.
• Tiangen Wu. Zaiying Lu. Comparison of histological effects between laser ablation and electrical  shock in myocardium in dogs. Pace and Heart 5(2): 77-80, 1991.
• Tiangen Wu, Zaiying Lu. The frontier of laser therapies in cardiovascular diseases. J of International  Medicine. 5: 226, 1987.
• Daowen Wang, Tiangen Wu, Zaiying Lu. Experimental studies of laser angioplasty in vitro. Chinese  J. of Cardiology. 4(3): 1862-66,1989.
• Kaori Sato, Tiangen Wu, Roger J. Laham, Robert B. Johnson, Pamela Douglas, Jianyi Li, Frank W. Sellke, Stuart  Bunting, Michael Simons, Mark J. Post. Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic Myocardial ischemia. Cardiosource Journal.37:2:616-623
• Tiangen Wu, Edward Kislauskis, Dennis Guberski, A model of macrovascular complication in the type 2 diabetic BBZDR rat. Diabetes, Vol 52, Sup 1, 2003, A170
• P.Marek, M. trocha, T. Wu, T.Jablonski, R. Bandarage, S.Richardson. Infrared thermography for detection of changes in hemodynamic status   of labia and clitoris after topical application of nitric oxide donor. ASBA annual meeting, June 4-8, 2000, Boston MA
• Takayuki Asahara, ChristopeBauters, Tiangen Wu, LupingZheng,    Donghui Chen, Jeffrey, M. Isner. Restoration of Endothelial function in hypercholesterolemic rabbit by intermittent administration of vascular endothelial growth factors. J. of America College of Cardiology. 1012-103, Feb,1995.
• Brogi E., Wu T., Kim E.., Namiki A., Jeffrey M. Isner. High glucose reduces basic FGF induced in vitro angiogenesis: implication for vascular impairment in diabetes mellitus. Circulation. 90(4): I-141,1994
• Tiangen Wu, Daowen Wang, Zaiying Lu. Effects of tetracycline in ultraviolet laser angioplasty. The 8^th Congress of International Society for Laser Surgery and Medicine. Taiwan, Nov., 91: 1989.
• Tiangen Wu, Zaiying Lu. Varied laser ablation of myocardium in vitro—- Histological observation and their related factors. The 8^th Congress of International Society for laser Surgery and Medicine. Taiwan, Nov., 92, 1992.

MEMBERSHIP

 

1996-Present Member of Sino-America Pharmaceutical Association

1997-Present Member of Massachusetts Biotechnology Council

2000-present Member of America Heart Association

2000-Present Member of America Diabetic Association